Sirtex Medical Limited
(ASX:SRX) has signed a deal to further expand its research into cancer therapies.
A new technology known as Carbon Cage Nanoparticles has been developed in conjunction with the Australian National University and designed to deliver radioactive substances to cancer sites within the body.
The master agreement will see the bio-tech company conduct several research projects on the technology in collaboration with Singaporean medical researchers.
The company has steadily boosted its share price over the year.
Sirtex Medical generated a net profit of $17.1 million in the 2012 financial year.
